Our data concluded that the EBV LMP-2-specific affibody and affitoxin molecules can be used for imaging diagnosis of LMP-2+ cells and have potentials for targeted therapy of EBV-derived, LMP-2+ NPC. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.